logo

IPCALAB vs KREBSBIO: Stock Comparison

IPCA LABORATORIES vs KREBS BIOCHEMICALS & INDUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

IPCA LABORATORIES is the larger company by market capitalisation. IPCA LABORATORIES shows a higher dividend yield, a higher ROCE and a higher net margin, while KREBS BIOCHEMICALS & IND shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

IPCALAB leads 6; KREBSBIO leads 3 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

IPCALABKREBSBIO

Valuation lens

What price are you paying?

Market CapContext only
₹47,950 Cr
₹125 Cr
P/E RatioKREBSBIO has the lower reading
36.61x
0x ✓
P/B RatioKREBSBIO has the lower reading
5.95x
0x ✓
EPSIPCALAB has the higher reading
₹15.84 ✓
₹-1.15
Book ValueContext only
₹375.4
—
Dividend YieldIPCALAB has the higher reading
0.31% ✓
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
IPCALAB is the larger company
₹47,950 Cr vs ₹125 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 36.61x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 5.95x
EPS
IPCALAB has higher earnings per share
₹15.84 vs ₹-1.15
Dividend Yield
IPCALAB has a higher dividend yield
0.31% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs 6.2%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs 0%
ROCE
IPCALAB has a higher ROCE
12.76% vs -15.89%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricIPCALABKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricIPCALABKREBSBIO
Live Price₹1,903.5₹57.48
Day Change-0.8%2.53%
Volume3.27 L3,570
52-Week High₹2,038₹76.85
52-Week Low₹1,251.6₹38.33
Distance from 52W High-6.6%-25.2%

Valuation

MetricIPCALABKREBSBIO
Market Cap₹47,950 Cr₹125 Cr
P/E Ratio36.61x0x
P/B Ratio5.95x0x
EPS₹15.84₹-1.15
Book Value₹375.4—
Dividend Yield0.31%0%

Growth

MetricIPCALABKREBSBIO
Revenue Growth (TTM YoY)6.2%11.6%
EPS Growth (TTM YoY)341.6%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricIPCALABKREBSBIO
ROE12.43%—
ROCE12.76%-15.89%
Net Margin11.83%-71.35%
Operating Margin17.09%-41.49%
Debt to Equity0.07x—

Shareholding

As of Sep 2026 • change vs previous quarter
MetricIPCALABKREBSBIO
Promoter Holding44.72%72.74%
FII Holding11.53%▲ 0.8 pp0.5%
DII Holding36.59%▼ 0.78 pp0%
Public Holding7.15%▼ 0.03 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IPCA LABORATORIES and KREBS BIOCHEMICALS & IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.